pocketful logo
Kabra Drugs Ltd logo

Kabra Drugs Ltd

NSE: BSE: 524322

₹27.04

(0.11%)

Sun, 22 Mar 2026, 02:42 am

mtf coin illustrationMTF 5x

Kabra Drugs Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    64.11

  • Net Profit

    -1.09

  • P/B

    1.07

  • Sector P/E

    39.77

  • P/E

    0

  • EV/EBITDA

    0

  • Debt/Equity (Industry)

    0.25

  • Interest Cover (Industry)

    11.42

  • ROCE (Industry)

    16.55

  • RONW (Industry)

    14.50

  • ROE

    0

  • ROCE

    0

  • Debt/Equity

    0.08

  • EPS (TTM)

    1.81

  • Dividend Yield

    0

  • Book Value

    10.96

  • Interest Cover

    0

Analysis

all

thumbs up icon

Pros

  • Kabra Drugs has no long term commitments.
  • Low level of unsold assets.
  • 524322 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
  • 524322 outperformed the Market in India which returned -14.5% over the past year.
thumbs up icon

Cons

  • Unable to evaluate Kabra Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kabra Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Kabra Drugs's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Operating cash flow is negative therefore debt is not well covered.
  • Kabra Drugs has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.

Read More

Financials

No Result Found

Read More

Ratios

No Result Found

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters00000
FII00000
DII00000
Public100100100100100
Government00000

Read More

Technical Analysis

RSI

34.36

MACD

-0.83

50 DMA

29.88

200 DMA

22.96

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic47.7439.4134.9631.0826.6322.7514.42
Fibonacci39.4136.2234.2631.0827.8925.9322.75
Camarilla32.8132.0531.2831.0829.7628.9928.23

Pivots Level: Classic

R3

+16.66

47.74

R2

+8.33

39.41

R1

+3.89

34.96

31.08
31.08
Pivot Point
LTP: 27.04

S1

-4.44

26.63

S2

-8.33

22.75

S3

-16.66

14.42

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    28.54

  • 20-EMA

    29.37

  • 30-EMA

    29.66

  • 50-EMA

    29.46

  • 100-EMA

    27.56

  • 200-EMA

    23.24

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
13 Feb 2026board-meetingsQuarterly Results
28 Nov 2025egm
13 Nov 2025board-meetingsQuarterly Results
02 Sept 2025agm
04 Dec 2024egm
02 Sept 2024agm
23 Jan 2024egm
02 Sept 2023agm
15 Sept 2022agm
02 Sept 2021agm

Read More

Peer Comparison

No Result Found

Kabra Drugs Ltd logo

Kabra Drugs Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Read More

Kabra Drugs Ltd About

Kabra Drugs is presently engaged in the business of Permaculture manufacturing and trading in pharma related products.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1989

Headquarters

CEO

Employees

Contact

Website icon

Website

http://www.kabradrugs.com

Email icon

Email

kabradrugs@gmail.com

Phone icon

Phone

Location icon

Location

270 Shastri Market Indore, , Indore, Madhya Pradesh, 452007

Read More

Kabra Drugs Ltd Company History

YearHistory
1989
  • The company Kabra Drugs Ltd was originally incorporated as a Pvt. Ltd company.
1992
  • The company was converted into a Public Ltd Company.
1993
  • The company came out with a public issue to part finance the expansion project.
  • The commercial production of the first phase of the project, the Ether section, commenced.
  • The implementation of the second phase involving manufacture of injectables neared completion.
2014
  • Kabra Drugs appointed M/s. M. Maheshwari & Associates, Practicing Company Secretary for Secretarial Audit.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
KRUTI SEVANTI DOSHISell13081031.8202 Jan 2026
KRUTI SEVANTI DOSHISell14319031.201 Jan 2026
KRUTI SEVANTI DOSHISell12600030.1924 Dec 2025
MIRAL HEMANTBHAI BHOOTSell11900027.5522 Dec 2025
VIJAY KUMAR REDDY VEERAMREDDYSell15051927.6320 Nov 2025
SELVAMURTHY AKILANDESWARIBuy19142226.8920 Nov 2025
SOUMYA MALANI .Buy15000027.6520 Nov 2025
ISHAAN TRADEFIN LLPBuy771721.8718 Jul 2025
ISHAAN TRADEFIN LLPSell13644222.2618 Jul 2025
ISHAAN TRADEFIN LLPBuy13739320.2516 Jul 2025

Read More

Kabra Drugs Ltd News

Kabra Drugs to Become Aanjaay Industries, Partners with Indonesia

Kabra Drugs Limited receives MCA approval for name change to Aanjaay Industries Limited and announces strategic joint venture with PT. Bhinneka Dwi Persada Indonesia for defence technology development and manufacturing.

07 Mar 2026

co actions results

Kabra Drugs Board Meet Set for Feb 13 Q3 Results

Kabra Drugs Limited has scheduled its board meeting for February 13, 2026, to consider and approve Q3FY26 unaudited financial results for the quarter ended December 31, 2025.

06 Feb 2026

co actions results

Kabra Drugs Gets Acquisition Approval & Expansion Plans

Kabra Drugs receives approval to acquire Vassmaan Automotive and announces plans to appoint 200 channel partners nationwide as part of its business expansion strategy.

01 Jan 2026

co actions results

Kabra Drugs Board Approves Name Change & Acquisition

Kabra Drugs Limited board approved company name change, strategic acquisition of Vassmaan Automotive, 200 channel partner agreement, and MOA amendments for EV, steel, and solar sectors diversification.

22 Dec 2025

stocks

Kabra Drugs Limited Schedules EGM to Appoint Independent Directors and Approve Key Resolutions

Kabra Drugs Limited will hold an Extraordinary General Meeting on December 26, 2025, to appoint Ms. Ritu Tiwari and Ms. Nikita Sinha as Non-Executive Independent Directors for five-year terms from October 8, 2025 to October 7, 2030. The meeting will also seek approval for revised remuneration of Rs. 72,00,000 per annum for Mr. Kuniamuthur Nanjappan Anand, authorization for loans and guarantees up to Rs. 200 crores under Section 186, and appointment of Mrs. Twinkle Agarwal as Secretarial Auditor for five years.

03 Dec 2025

corporate action

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800